Based on the study results, the therapeutic efficacy of gefitinib and erlotinib has been tested on lung adenocarcinoma patients with EGFR mutations, and both medications were found to show 100% efficacy of the tested patients. This evidence concerns the gene EGFR and lung adenocarcinoma.